Cargando…

Optical coherence tomography angiography analysis of changes in the foveal avascular zone in eyes with diabetic macular edema treated with intravitreal anti-vascular endothelial growth factor

BACKGROUND: To analyze the changes in foveal avascular zone (FAZ) area, perimeter, and circularity in the superficial (SCP) and deep (DCP) capillary plexuses in eyes with diabetic macular edema (DME) treated with intravitreal anti-VEGF using optical coherence tomography angiography (OCTA). METHODS:...

Descripción completa

Detalles Bibliográficos
Autores principales: Bromeo, Albert John, Grulla-Quilendrino, Patricia, Antolin, Ruth Camille, Salcedo, Emil Joshua John, Arcinue, Cheryl A., De Jesus, Ralph Anthony, Veloso, Amadeo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9419407/
https://www.ncbi.nlm.nih.gov/pubmed/36028899
http://dx.doi.org/10.1186/s40942-022-00406-z
_version_ 1784777168114417664
author Bromeo, Albert John
Grulla-Quilendrino, Patricia
Antolin, Ruth Camille
Salcedo, Emil Joshua John
Arcinue, Cheryl A.
De Jesus, Ralph Anthony
Veloso, Amadeo
author_facet Bromeo, Albert John
Grulla-Quilendrino, Patricia
Antolin, Ruth Camille
Salcedo, Emil Joshua John
Arcinue, Cheryl A.
De Jesus, Ralph Anthony
Veloso, Amadeo
author_sort Bromeo, Albert John
collection PubMed
description BACKGROUND: To analyze the changes in foveal avascular zone (FAZ) area, perimeter, and circularity in the superficial (SCP) and deep (DCP) capillary plexuses in eyes with diabetic macular edema (DME) treated with intravitreal anti-VEGF using optical coherence tomography angiography (OCTA). METHODS: This prospective observational study included 56 eyes from 32 patients with DME that received intravitreal anti-VEGF. OCTA images were obtained at baseline and 1, 3, and 6 months of follow-up. The outcome measures were FAZ area, perimeter, and circularity in both the SCP and DCP, as well as central subfield thickness (CST) and best-corrected visual acuity (BCVA). RESULTS: The mean number of intravitreal anti-VEGF injections received during the observation period was 4.60 ± 0.82 (range: 3–6). The FAZ area, perimeter, and circularity were statistically unchanged at all observation points in both the SCP (p = 0.772, p = 0.405, p = 0.157, respectively) and the DCP (p = 0.620, p = 0.769, p = 0.481, respectively). Despite having no change in the FAZ parameters, there was still a statistically significant decrease in CST (p < 0.001) as well as a statistically significant increase in BCVA (p = 0.004) during the observation period. CONCLUSIONS: The FAZ area, perimeter, and circularity in the SCP and DCP as measured by OCTA remained stable during the first 6 months of intravitreal anti-VEGF therapy in eyes with DME. While there were no significant changes in the FAZ, treatment with intravitreal anti-VEGF still resulted in decreased CST and improved BCVA.
format Online
Article
Text
id pubmed-9419407
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-94194072022-08-28 Optical coherence tomography angiography analysis of changes in the foveal avascular zone in eyes with diabetic macular edema treated with intravitreal anti-vascular endothelial growth factor Bromeo, Albert John Grulla-Quilendrino, Patricia Antolin, Ruth Camille Salcedo, Emil Joshua John Arcinue, Cheryl A. De Jesus, Ralph Anthony Veloso, Amadeo Int J Retina Vitreous Original Article BACKGROUND: To analyze the changes in foveal avascular zone (FAZ) area, perimeter, and circularity in the superficial (SCP) and deep (DCP) capillary plexuses in eyes with diabetic macular edema (DME) treated with intravitreal anti-VEGF using optical coherence tomography angiography (OCTA). METHODS: This prospective observational study included 56 eyes from 32 patients with DME that received intravitreal anti-VEGF. OCTA images were obtained at baseline and 1, 3, and 6 months of follow-up. The outcome measures were FAZ area, perimeter, and circularity in both the SCP and DCP, as well as central subfield thickness (CST) and best-corrected visual acuity (BCVA). RESULTS: The mean number of intravitreal anti-VEGF injections received during the observation period was 4.60 ± 0.82 (range: 3–6). The FAZ area, perimeter, and circularity were statistically unchanged at all observation points in both the SCP (p = 0.772, p = 0.405, p = 0.157, respectively) and the DCP (p = 0.620, p = 0.769, p = 0.481, respectively). Despite having no change in the FAZ parameters, there was still a statistically significant decrease in CST (p < 0.001) as well as a statistically significant increase in BCVA (p = 0.004) during the observation period. CONCLUSIONS: The FAZ area, perimeter, and circularity in the SCP and DCP as measured by OCTA remained stable during the first 6 months of intravitreal anti-VEGF therapy in eyes with DME. While there were no significant changes in the FAZ, treatment with intravitreal anti-VEGF still resulted in decreased CST and improved BCVA. BioMed Central 2022-08-26 /pmc/articles/PMC9419407/ /pubmed/36028899 http://dx.doi.org/10.1186/s40942-022-00406-z Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Original Article
Bromeo, Albert John
Grulla-Quilendrino, Patricia
Antolin, Ruth Camille
Salcedo, Emil Joshua John
Arcinue, Cheryl A.
De Jesus, Ralph Anthony
Veloso, Amadeo
Optical coherence tomography angiography analysis of changes in the foveal avascular zone in eyes with diabetic macular edema treated with intravitreal anti-vascular endothelial growth factor
title Optical coherence tomography angiography analysis of changes in the foveal avascular zone in eyes with diabetic macular edema treated with intravitreal anti-vascular endothelial growth factor
title_full Optical coherence tomography angiography analysis of changes in the foveal avascular zone in eyes with diabetic macular edema treated with intravitreal anti-vascular endothelial growth factor
title_fullStr Optical coherence tomography angiography analysis of changes in the foveal avascular zone in eyes with diabetic macular edema treated with intravitreal anti-vascular endothelial growth factor
title_full_unstemmed Optical coherence tomography angiography analysis of changes in the foveal avascular zone in eyes with diabetic macular edema treated with intravitreal anti-vascular endothelial growth factor
title_short Optical coherence tomography angiography analysis of changes in the foveal avascular zone in eyes with diabetic macular edema treated with intravitreal anti-vascular endothelial growth factor
title_sort optical coherence tomography angiography analysis of changes in the foveal avascular zone in eyes with diabetic macular edema treated with intravitreal anti-vascular endothelial growth factor
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9419407/
https://www.ncbi.nlm.nih.gov/pubmed/36028899
http://dx.doi.org/10.1186/s40942-022-00406-z
work_keys_str_mv AT bromeoalbertjohn opticalcoherencetomographyangiographyanalysisofchangesinthefovealavascularzoneineyeswithdiabeticmacularedematreatedwithintravitrealantivascularendothelialgrowthfactor
AT grullaquilendrinopatricia opticalcoherencetomographyangiographyanalysisofchangesinthefovealavascularzoneineyeswithdiabeticmacularedematreatedwithintravitrealantivascularendothelialgrowthfactor
AT antolinruthcamille opticalcoherencetomographyangiographyanalysisofchangesinthefovealavascularzoneineyeswithdiabeticmacularedematreatedwithintravitrealantivascularendothelialgrowthfactor
AT salcedoemiljoshuajohn opticalcoherencetomographyangiographyanalysisofchangesinthefovealavascularzoneineyeswithdiabeticmacularedematreatedwithintravitrealantivascularendothelialgrowthfactor
AT arcinuecheryla opticalcoherencetomographyangiographyanalysisofchangesinthefovealavascularzoneineyeswithdiabeticmacularedematreatedwithintravitrealantivascularendothelialgrowthfactor
AT dejesusralphanthony opticalcoherencetomographyangiographyanalysisofchangesinthefovealavascularzoneineyeswithdiabeticmacularedematreatedwithintravitrealantivascularendothelialgrowthfactor
AT velosoamadeo opticalcoherencetomographyangiographyanalysisofchangesinthefovealavascularzoneineyeswithdiabeticmacularedematreatedwithintravitrealantivascularendothelialgrowthfactor